Document is current
Any future updates will be listed below
-
Authors
Rivera-Caravaca, José Miguel
Soler-Espejo, Eva
Ramos-Bratos, María Pilar
López-Gálvez, Raquel
González-Lozano, Eduardo
Lip, Gregory Y. H.
Marín, Francisco
Roldán, Vanessa
-
Funding
Funding for this research was provided by:
Fundación Seneca (21919/JLI/22)
Fundación Seneca (21919/JLI/22)
Fundación Seneca (21919/JLI/22)
Instituto de Salud Carlos III (PI17/01375)
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 31 May 2025
First Online: 10 July 2025
Declarations
:
: Gregory Y.H. Lip: consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 899871. José Miguel Rivera-Caravaca: Consultant for Idorsia Pharmaceuticals LTD. Francisco Marín is consultant and speaker for Boehringer-Ingelheim and BMS/Pfizer. There is nothing to disclose for other authors.
